Not Yet RecruitingNot Applicable

Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice

South Korea7,000 participantsStarted 2026-04-30

Plain-language summary

This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea. Patients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged ≥19 years * Patients requiring NSAIDs therapy * Patients requiring prevention of NSAIDs-induced peptic ulcer * Patients prescribed Fexuclue Tablet 20 mg * Patients who provide written informed consent Exclusion Criteria: * Hypersensitivity to Fexuclue or its components * Severe hepatic impairment * Pregnant or breastfeeding women * Patients considered inappropriate by investigator

What they're measuring

Proportion of Patients with Peptic Ulcer Symptom Occurrence at Week 2

Timeframe: Week 2

Trial details

NCT IDNCT07558707

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-04-30

Contact for this trial

SoHeui Kim

82-10-2994-5887 2210325@daewoong.co.kr

View on ClinicalTrials.gov More Peptic Ulcer trials